Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen?
Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in eva...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Stemmler, H. J. [verfasserIn] Stieber, P. [verfasserIn] Heinemann, V. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Walter de Gruyter ; 2005 |
|---|
| Anmerkung: |
Copyright © 2004 by Walter de Gruyter GmbH & Co. KG |
|---|---|
| Umfang: |
6 |
| Reproduktion: |
Walter de Gruyter Online Zeitschriften |
|---|---|
| Übergeordnetes Werk: |
In: 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 ; year:2005 ; number:2 ; day:01 ; month:06 ; pages:103-108 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1515/LabMed.2004.017 |
|---|
| Katalog-ID: |
NLEJ247330701 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ247330701 | ||
| 003 | DE-627 | ||
| 005 | 20230506082247.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220814s2005 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1515/LabMed.2004.017 |2 doi | |
| 028 | 5 | 2 | |a artikel_Grundlieferung.pp |
| 035 | |a (DE-627)NLEJ247330701 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Stemmler, H. J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| 264 | 1 | |b Walter de Gruyter |c 2005 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2004 by Walter de Gruyter GmbH & Co. KG | ||
| 520 | |a Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. | ||
| 533 | |f Walter de Gruyter Online Zeitschriften | ||
| 700 | 1 | |a Stieber, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Heinemann, V. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |g 28(2005), 2 vom: 01. Juni, Seite 103-108 |
| 773 | 1 | 8 | |g volume:28 |g year:2005 |g number:2 |g day:01 |g month:06 |g pages:103-108 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1515/LabMed.2004.017 |z Deutschlandweit zugänglich |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DGR | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2005 |e 2 |b 01 |c 06 |h 103-108 |g 6 | ||
| author_variant |
h j s hj hjs p s ps v h vh |
|---|---|
| matchkey_str |
stemmlerhjstieberpheinemannv:2005----:ac19ieiselciaigrcdrsnepnevlainfainsnegighmteayomtsaipnraicnekndeieidsa9biersoseautovnhmteaetsheadlep |
| hierarchy_sort_str |
2005 |
| publishDate |
2005 |
| allfields |
10.1515/LabMed.2004.017 doi artikel_Grundlieferung.pp (DE-627)NLEJ247330701 DE-627 ger DE-627 rakwb Stemmler, H. J. verfasserin aut Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? Walter de Gruyter 2005 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Walter de Gruyter Online Zeitschriften Stieber, P. verfasserin aut Heinemann, V. verfasserin aut In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 https://doi.org/10.1515/LabMed.2004.017 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 2 01 06 103-108 6 |
| spelling |
10.1515/LabMed.2004.017 doi artikel_Grundlieferung.pp (DE-627)NLEJ247330701 DE-627 ger DE-627 rakwb Stemmler, H. J. verfasserin aut Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? Walter de Gruyter 2005 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Walter de Gruyter Online Zeitschriften Stieber, P. verfasserin aut Heinemann, V. verfasserin aut In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 https://doi.org/10.1515/LabMed.2004.017 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 2 01 06 103-108 6 |
| allfields_unstemmed |
10.1515/LabMed.2004.017 doi artikel_Grundlieferung.pp (DE-627)NLEJ247330701 DE-627 ger DE-627 rakwb Stemmler, H. J. verfasserin aut Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? Walter de Gruyter 2005 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Walter de Gruyter Online Zeitschriften Stieber, P. verfasserin aut Heinemann, V. verfasserin aut In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 https://doi.org/10.1515/LabMed.2004.017 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 2 01 06 103-108 6 |
| allfieldsGer |
10.1515/LabMed.2004.017 doi artikel_Grundlieferung.pp (DE-627)NLEJ247330701 DE-627 ger DE-627 rakwb Stemmler, H. J. verfasserin aut Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? Walter de Gruyter 2005 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Walter de Gruyter Online Zeitschriften Stieber, P. verfasserin aut Heinemann, V. verfasserin aut In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 https://doi.org/10.1515/LabMed.2004.017 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 2 01 06 103-108 6 |
| allfieldsSound |
10.1515/LabMed.2004.017 doi artikel_Grundlieferung.pp (DE-627)NLEJ247330701 DE-627 ger DE-627 rakwb Stemmler, H. J. verfasserin aut Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? Walter de Gruyter 2005 6 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Copyright © 2004 by Walter de Gruyter GmbH & Co. KG Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Walter de Gruyter Online Zeitschriften Stieber, P. verfasserin aut Heinemann, V. verfasserin aut In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 https://doi.org/10.1515/LabMed.2004.017 Deutschlandweit zugänglich GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE AR 28 2005 2 01 06 103-108 6 |
| source |
In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 |
| sourceStr |
In 28(2005), 2 vom: 01. Juni, Seite 103-108 volume:28 year:2005 number:2 day:01 month:06 pages:103-108 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| authorswithroles_txt_mv |
Stemmler, H. J. @@aut@@ Stieber, P. @@aut@@ Heinemann, V. @@aut@@ |
| publishDateDaySort_date |
2005-06-01T00:00:00Z |
| id |
NLEJ247330701 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247330701</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082247.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/LabMed.2004.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247330701</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stemmler, H. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Copyright © 2004 by Walter de Gruyter GmbH & Co. KG</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stieber, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinemann, V.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="g">28(2005), 2 vom: 01. Juni, Seite 103-108</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:103-108</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/LabMed.2004.017</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">103-108</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Walter de Gruyter Online Zeitschriften |
| author |
Stemmler, H. J. |
| spellingShingle |
Stemmler, H. J. Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| authorStr |
Stemmler, H. J. |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| publisher |
Walter de Gruyter |
| publisherStr |
Walter de Gruyter |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| isfreeaccess_txt |
false |
| title |
Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| ctrlnum |
(DE-627)NLEJ247330701 |
| title_full |
Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| author_sort |
Stemmler, H. J. |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2005 |
| contenttype_str_mv |
txt |
| container_start_page |
103 |
| author_browse |
Stemmler, H. J. Stieber, P. Heinemann, V. |
| container_volume |
28 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Stemmler, H. J. |
| doi_str_mv |
10.1515/LabMed.2004.017 |
| author2-role |
verfasserin |
| title_sort |
can ca19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / kann die kinetik des ca19-9 bei der response-evaluation von chemotherapeutisch behandelten patienten mit metastasierendem pankreaskarzinom bildgebende verfahren ersetzen? |
| title_auth |
Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| abstract |
Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Copyright © 2004 by Walter de Gruyter GmbH & Co. KG |
| abstractGer |
Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Copyright © 2004 by Walter de Gruyter GmbH & Co. KG |
| abstract_unstemmed |
Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival. Copyright © 2004 by Walter de Gruyter GmbH & Co. KG |
| collection_details |
GBV_USEFLAG_U ZDB-1-DGR GBV_NL_ARTICLE |
| container_issue |
2 |
| title_short |
Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen? |
| url |
https://doi.org/10.1515/LabMed.2004.017 |
| remote_bool |
true |
| author2 |
Stieber, P. Heinemann, V. |
| author2Str |
Stieber, P. Heinemann, V. |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1515/LabMed.2004.017 |
| up_date |
2024-07-06T10:22:21.219Z |
| _version_ |
1803824756129005568 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ247330701</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506082247.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220814s2005 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1515/LabMed.2004.017</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">artikel_Grundlieferung.pp</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ247330701</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Stemmler, H. J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Can CA19-9 kinetics replace imaging procedures in response evaluation of patients undergoing chemotherapy for metastatic pancreatic cancer? / Kann die Kinetik des CA19-9 bei der Response-Evaluation von chemotherapeutisch behandelten Patienten mit metastasierendem Pankreaskarzinom bildgebende Verfahren ersetzen?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="b">Walter de Gruyter</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Copyright © 2004 by Walter de Gruyter GmbH & Co. KG</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background: Response evaluation by standard imagingprocedures such as computed tomography (CT) may bedifficult in patients undergoing chemotherapy foradvanced and metastatic pancreatic cancer. The aim ofthe study was to determine whether kinetics of CA19-9levels can replace imaging procedures in evaluating theresponse to chemotherapy in these patients. Patients and methods: Patients with advanced ormetastatic pancreatic cancer were included in the study.Patients received a combination chemotherapy consistingof gemcitabine (1000 mg m−2 d1, 8, 15) and cisplatin(50 mg m−2 d1, 15) repeated on day 29. Treatment wascontinued until unacceptable toxicity or disease progressionoccurred. CA19-9 levels were measured directlybefore each cytotoxic treatment cycle. CA19-9 responsewas defined by a ≥50% decrease in CA19-9 serum levelswithin two months after treatment initiation. Results: A total of 77 patients with initially elevatedCA19-9 levels were included for evaluation (f/m = 26/61;stage 3/4 = 24/63). Out of 15 patients who had respondedto chemotherapy regarding imaging criteria (CR 4, PR11, OR 19.5%), 14 patients were classified as CA19-9responders. Although 62 patients had not responded tochemotherapy by CT-imaging criteria, 29 patients fulfilledthe criterion of a CA19-9 responder. The low value ofCA19-9 kinetics in predicting imaging results (positivepredictive value 32.5%) seems to be clinically irrelevantsince CA19-9 responders, independent of imaging criteria,have a significant improvement of survival timecompared to non-responders (295 days; 95%CI:285–445 vs 174 days; 95%CI: 134–198; p = 0.022). Conclusion: CA19-9 kinetics are unable to predicttumor response regarding imaging criteria. However, thekinetic of CA19-9 in a patient undergoing chemotherapyfor pancreatic cancer seems to be a reliable indicator inpredicting survival.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Walter de Gruyter Online Zeitschriften</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stieber, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heinemann, V.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="g">28(2005), 2 vom: 01. Juni, Seite 103-108</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:28</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:103-108</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1515/LabMed.2004.017</subfield><subfield code="z">Deutschlandweit zugänglich</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DGR</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">28</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">103-108</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.399625 |